Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Announce Earnings of -$0.51 Per Share

Wall Street analysts expect Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) to report earnings per share (EPS) of ($0.51) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Autolus Therapeutics’ earnings. The lowest EPS estimate is ($0.61) and the highest is ($0.45). Autolus Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Autolus Therapeutics will report full-year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($1.73). For the next fiscal year, analysts expect that the business will post earnings of ($1.98) per share, with EPS estimates ranging from ($2.38) to ($1.60). Zacks’ EPS averages are an average based on a survey of analysts that cover Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same period in the prior year, the business earned ($0.82) EPS.

AUTL has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Autolus Therapeutics in a research note on Monday, December 20th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research note on Thursday, March 10th. Finally, Zacks Investment Research lowered Autolus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Buy” and a consensus price target of $13.60.

A number of institutional investors have recently bought and sold shares of the stock. Syncona Portfolio Ltd purchased a new position in Autolus Therapeutics during the fourth quarter worth about $38,130,000. Frazier Management LLC grew its position in Autolus Therapeutics by 6.1% during the fourth quarter. Frazier Management LLC now owns 3,746,857 shares of the company’s stock worth $19,446,000 after buying an additional 216,200 shares in the last quarter. Pendal Group Ltd grew its position in Autolus Therapeutics by 2.6% during the fourth quarter. Pendal Group Ltd now owns 1,444,802 shares of the company’s stock worth $7,499,000 after buying an additional 36,485 shares in the last quarter. Woodline Partners LP purchased a new position in Autolus Therapeutics during the fourth quarter worth about $4,868,000. Finally, LGT Capital Partners LTD. purchased a new position in Autolus Therapeutics during the first quarter worth about $2,085,000. Institutional investors and hedge funds own 68.28% of the company’s stock.

NASDAQ:AUTL opened at $4.04 on Thursday. Autolus Therapeutics has a 52-week low of $3.42 and a 52-week high of $8.23. The firm has a market cap of $367.28 million, a price-to-earnings ratio of -2.04 and a beta of 1.54. The business’s fifty day moving average is $4.17 and its 200 day moving average is $5.06.

Autolus Therapeutics Company Profile (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Further Reading